Author

B. D. Quinlan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Organism:mouse· 1 Assay:protein sequence· 1

Frequent Co-Authors

M. Farzan· 4 shared G. Zhong· 3 shared A. Ojha· 2 shared H. Choe· 2 shared H. Mou· 2 shared L. Zhang· 2 shared M. S. Parcells· 2 shared W. He· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

M. Farzan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Efficient reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire

T. Ou, W. He, B. D. Quinlan, Y. Guo, P. Karunadharma, H. Park, M. Davis-Gardner, M. Tran, Y. Yin, X. Zhang, H. Wang, G. Zhong, M. Farzan

The paper reprograms human B cells to express HCDR3 regions of HIV-1 bNAbs, enabling diverse and physiologic repertoires that efficiently bind HIV-1 antigens.

bioRxiv · Apr 1, 2021Immunology

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro

T. Xiao, J. Lu, J. Zhang, R. I. Johnson, L. G. A. McKay, N. Storm, C. L. Lavine, H. Peng, Y. Cai, S. Rits-Volloch, S. Lu, B. D. Quinlan, M. Farzan, M. S. Seaman, A. Griffiths, B. Chen

This study creates a trimeric ACE2 variant with high affinity for SARS-CoV-2 spike protein and shows it inhibits viral infection in cell culture.

Nature Structural & Molecular Biology · Feb 1, 2021Peer-reviewedMicrobiology

An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines

B. D. Quinlan, W. Li, H. Mou, L. Zhang, J. Chang, S. Peng, A. Ojha, R. Tavora, M. S. Parcells, G. G. Luo, W. Li, G. Zhong, H. Choe, M. Farzan

This paper shows that an engineered RBD with glycosylation sites improves immunogenicity and expression efficiency in SARS-CoV-2 vaccines.

bioRxiv · Nov 18, 2020Microbiology

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement

B. D. Quinlan, H. Mou, L. Zhang, Y. Gao, W. He, A. Ojha, M. S. Parcells, G. Luo, W. Li, G. Zhong, H. Choe, M. Farzan

This study shows that immunization with SARS-CoV-2 RBD elicits potent neutralizing antibodies without antibody-dependent enhancement in rodents.

bioRxiv · Apr 10, 2020 · PreprintMicrobiology